|Articles|June 26, 2015

GSK to Sell Legacy Vaccines to Pfizer

June 26, 2015.

GlaxoSmithKline has announced that it will sell its meningitis vaccines Nimenrix and Mencevax to Pfizer Ireland Pharmaceuticals. The €115m sale is subject to final European Commission approval, other regulatory approvals, and other customary closing conditions and is expected to close before the end of the year.

Source: GSK

Newsletter

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Related Content

From Diagnosis to Design: How Physician-Scientists Are Building Future-Ready Pharma Organizations

ByEmmanuelle Clerisme-Beaty, M.D.

August 10th 2026

Matt Farrell

Generating Commercial Evidence from Agentic Field and Brand Engagement to Accelerate Launch Performance

August 10th 2026

stock.adobe.com technology

Inizio Launches Connected Insights for Global Medical Information

ByNicholas Jacobus

July 30th 2026

The Ron Lanton Report

The Ron Lanton Report: The Human Bottleneck

ByRon Lanton,Nicholas Jacobus

July 29th 2026

Mike Faddoul, Partner, Audit & Assurance, Crowe

Why Gross-to-Net Internal Controls Should Be a Launch Priority for Specialty Pharma Companies

July 27th 2026

Trending on PharmExec

Everything You Need to Know About the AstraZeneca–Bristol Myers Squibb Merger Rumors

Executive Order Cuts Recommended Childhood Vaccines Down to 11: Report

BeOne Medicines Enters Collaboration with Revolution Medicines for Oncology Therapies

Pharmaceutical Executive Daily: Jazz Acquires Actio Bioscience

The Science of Targeting Multiple Immune Components in ITP: Q&A with Dr. Srikanth Nagalla